Epitalon

Telomerase and Telomere Research

Telomere-biology preparations account for the most commercially emphasized line of Epitalon research. The foundational reference is Khavinson, Bondarev, and Butyugov (2003), a three-page Russian-language short-communication in Bulletin of Experimental Biology and Medicine reporting telomerase activity and telomere-length changes in a single primary culture of human fetal lung fibroblasts using the TRAP (telomeric repeat amplification protocol) readout^[2].

The 2003 paper went 22 years without independent Western primary replication. The first credible independent replication, Al-Dulaimi et al. at Brunel University London (Biogerontology, September 2025), confirmed telomere extension and reported a 12-fold hTERT upregulation in normal cells across six cell lines but documented a 10-fold activation of the Alternative Lengthening of Telomeres (ALT) recombination pathway in 21NT breast cancer cells^[6]. The ALT-in-cancer-cells finding is a safety-relevant signal that the prior Khavinson-affiliated literature did not document and that has not been replicated in additional laboratories.

For regulatory context, Geron Corporation's anti-telomerase oncology drug imetelstat was approved by the FDA in 2024 for myelodysplastic syndromes, illustrating that telomerase is a validated drug target as an inhibitor in oncology rather than as an activator. No telomerase-activator compound has reached FDA approval for any indication as of May 2026.

Rodent Lifespan and Geroscience Research

Rodent lifespan preparations have been a sustained focus in the Khavinson laboratory and the affiliated Anisimov group at the N.N. Petrov Research Institute of Oncology in Saint Petersburg. The most-cited lifespan study is Anisimov et al. (2003) in Biogerontology, a single-colony Spontaneously Hypertensive Rat (SHR) preparation with n=54 per arm receiving subcutaneous administration of 1.0 microgram per mouse monthly^[7].

The 2003 SHR study reported no mean lifespan extension as the primary endpoint, a +12.3% maximum lifespan effect, a +13.3% last-decile-survivor lifespan effect, and a 6-fold reduction in spontaneous leukemia incidence. The study has not been replicated by the National Institute on Aging Interventions Testing Program (NIH ITP), and modern geroscience meta-analyses (Ali et al. 2023 and 2024) have excluded Khavinson and Anisimov SHR studies on the grounds of unusually short control-arm lifespans inflating apparent extension effects^[8].

For class context, the geroscience literature evaluates compounds including rapamycin (FDA-approved mTOR inhibitor with NIH ITP-replicated mouse lifespan extension), metformin (FDA-approved Complex I / AMPK modulator with the ongoing TAME human trial), and dietary supplement-channel candidates such as NAD+ precursors and spermidine. No telomerase-activator candidate has cleared NIH ITP replication as of May 2026.

Pineal Chronobiology and Melatonin Research

Pineal chronobiology preparations are the line of Epitalon research most directly relevant to the indication on the July 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) docket. The most-cited work is Korkushko et al. (2011), a 15-year follow-up of elderly Russian cohorts evaluating pineal melatonin secretion patterns^[9].

A central provenance caveat applies to the chronobiology literature: the Korkushko 15-year follow-up tested Epithalamin (the polydisperse bovine pineal acid-acetone extract that is a Russian Federation registered drug for menopause, infertility, and hormone-dependent tumors) rather than synthetic AEDG. The extract contains approximately 3% free amino acids, 23% dipeptides, 51% tripeptides, 22% tetrapeptides, and 0.7% pentapeptides. Whether observations recorded with the Epithalamin extract transfer to the synthetic 4-amino-acid tetrapeptide is an open question that the published literature has not resolved at the time of writing.

Vendor copy across the broader Epitalon market routinely conflates Epithalamin-extract findings with synthetic AEDG findings. This is the same molecule-versus-nomenclature pattern documented for thymosin beta-4 versus the TB-500 7-mer (Ac-LKKTETQ) in laboratory research commerce. Confirming whether a cited study used synthetic AEDG or Epithalamin extract is the first methodology check for any chronobiology claim in this literature.

Retinal and Ophthalmic Preparations

Retinal research in the Khavinson laboratory has examined Epitalon administration in retinitis pigmentosa patient cohorts and in preclinical retinal preparations. The most-cited human-cohort report is Khavinson and Razumovsky (2002), an uncontrolled trial in n=162 patients receiving parabulbar Epitalon administration with electroretinographic and visual-function readouts^[10].

The 2002 retinitis pigmentosa report lacks a placebo control arm, lacks randomization, and lacks independent replication outside the Khavinson research orbit. The uncontrolled design is the dominant methodology pattern across the Khavinson human-cohort literature in Russian elderly populations, which the published literature characterizes as primarily observational rather than randomized.

No Phase 2 or Phase 3 controlled ophthalmic trial of Epitalon has been registered with ClinicalTrials.gov or with EU Clinical Trials Register as of May 2026. A query of ClinicalTrials.gov v2 API for Epitalon, Epithalon, Epithalamin, and AEDG peptide returns zero NCT records, an unusually clean Russian-registry-only profile in the indexed peptide literature.

Khavinson Short-Peptide Family Research

Epitalon sits within the broader Khavinson short-peptide bioregulator program, a catalog of approximately 30 organ-specific tetrapeptides and tripeptides developed at IBG Saint Petersburg from the 1970s onward. The peptides were synthesized based on amino-acid compositional analysis of organ-specific tissue extracts: Epithalamin (pineal) for Epitalon; Cortexin precursors (cortex) for Cortexin; Thymalin precursors (thymus) for Thymalin; and similar parent-extract lineages for Cardiogen (AED), Pinealon (EDR), Vesugen, Pancragen, Glandokort, Testagen, Ovagen, Crystagen, Visoluten, Suprefort, Prostamax, and Livagen.

Within the Khavinson catalog, only 6 of the bioregulators (including Cortexin and Thymalin) hold Russian Federation drug registration as pharmaceuticals. The remaining approximately 64 are categorized in Russian regulatory practice as food supplements (БАД, Biologically Active Additives). Synthetic Epitalon sits in the food-supplement category, not the registered-drug category. The Russian commercial vehicle NPCRIZ (Scientific-Production Center of Revitalization and Health, founded 2010) distributes the broader Khavinson catalog through approximately 300 representative offices across 25 countries.

Vladimir Khavinson, the founding scientist of the IBG Saint Petersburg program, died on January 6, 2024 at age 77. Post-Khavinson institutional succession at IBG and at NPCRIZ has not been publicly clarified at the time of writing.

Replication, Citation Concentration, and Clinical Status

Epitalon-specific PubMed indexing returns an estimated 80-130 papers (precise count limited by access throttling), among the smallest primary corpora in the indexed research-peptide literature. Within that corpus, approximately 75-90% of papers have Khavinson lab first or last authorship or IBG Saint Petersburg institutional affiliation, an unusually high single-laboratory citation concentration (exceeding the Sikirić approximately 87% concentration in the BPC-157 literature). Anisimov, Goncharova, Sevostianova, Korkushko, Trofimov, Mikhailova, and Vanyushin form the core collaborator lineage^[1][4][7].

Five of the five most-cited Epitalon primary papers originate from the IBG Saint Petersburg cluster. The first credible independent Western replication of the 2003 telomerase paper, Al-Dulaimi et al. at Brunel University London (Biogerontology, September 2025), reached the literature 22 years after the original short-communication and arrived after Vladimir Khavinson's death^[6].

The Russian regulatory status of synthetic Epitalon is the food-supplement category (БАД), not the registered-drug category. The predecessor pineal extract Epithalamin is registered as a Russian drug; the synthetic AEDG tetrapeptide is not. Marketing-derived statements characterizing Epitalon as a Russian-approved drug or as an FDA-approved or globally approved drug are not supported by the regulatory record.

In the United States, the FDA placed Epitalon in 503A Category 2 (Do-Not-Compound, may present significant safety risks) in September 2023. Epitalon is in the 12-peptide reclassification batch announced April 22, 2026. The Pharmacy Compounding Advisory Committee will review Epitalon (free base and Epitalon acetate) on Day 2 of the July 23-24, 2026 PCAC meeting; the verbatim docket text in Federal Register document 2026-07361 lists the proposed use as 'insomnia.' The docket does not list telomerase activation, longevity, or anti-aging effects as proposed uses. World Anti-Doping Agency listings do not name Epitalon explicitly; the molecule is captured by the S0 (Non-Approved Substances) catch-all category, banned at all times with no Therapeutic Use Exemption pathway. Tailor Made Compounding Pharmacy's 2020 federal plea named Epitalon explicitly in the distribution list; the April 2026 Watkins indictment did not.